文献速递神经免疫

奥瑞利珠单抗治疗早期复发缓解型多发性硬化:IIIb期ENSEMBLE研究4年单臂开放标签试验

Ocrelizumab in Early-Stage Relapsing-Remitting Multiple Sclerosis: The Phase IIIb ENSEMBLE 4-Year, Single-Arm, Open-Label Trial.
PubMed 文献 · Neurology · 2024-12-03

ENSEMBLE是一项前瞻性、4年、国际多中心、单臂、开放标签的IIIb期研究,纳入678例未接受过治疗、病程≤3年的早期复发缓解型多发性硬化患者,每24周静脉给予奥瑞利珠单抗600 mg。192周时66.4%的患者达到NEDA-3,调整年复发率为0.020(95%CI 0.015-0.027),安全性与此前已知特征一致。

要点

  • 192周时394/593例(66.4%)达到NEDA-3,85.0%无MRI活动,90.9%无复发。
  • 192周调整年复发率为0.020(95%CI 0.015-0.027)。
  • 安全性未观察到新的或非预期信号,与此前已知特征一致。

核心结论

  • 在ENSEMBLE研究中,多数接受奥瑞利珠单抗治疗4年的患者基于临床和MRI指标无疾病活动,安全性与此前已知特征一致。
  • 尽管该单臂研究缺乏平行对照组比较结局指标,作者认为观察到的阳性获益-风险特征可能为将奥瑞利珠单抗作为新诊断早期复发型多发性硬化一线治疗提供信心。

研究设计与样本

  • ENSEMBLE为前瞻性、4年、国际、多中心、单臂、开放标签的IIIb期研究。
  • 纳入未接受过治疗、年龄18-55岁、早期复发缓解型多发性硬化(病程≤3年)、EDSS评分≤3.5、且既往12个月内≥1次临床报告复发或MRI≥1项脑炎症活动征象的患者。
  • 患者每24周静脉接受奥瑞利珠单抗600 mg,有效性终点观察192周,对意向治疗人群进行描述性分析。
  • 研究注册于ClinicalTrials.gov(NCT03085810),2017年3月16日首次提交,2017年3月27日首例患者入组。

主要发现

  • 基线(N=678)符合早期复发缓解型多发性硬化特征:n=539例患者为64.6%女性、年龄40岁及以下;中位年龄31.0岁;自多发性硬化症状出现0.78年、自复发缓解型多发性硬化诊断0.24年;基线EDSS评分均值(SD)1.71(0.95)。
  • 第192周时多数患者达到NEDA-3(n=394/593,66.4%),85.0%无MRI活动,90.9%无复发,81.8%在研究期间无24周确认的残疾进展。
  • 第192周调整年复发率低(0.020,95%CI 0.015-0.027)。
  • 神经丝轻链(NfL)水平分别在第48周和第192周降至并维持于健康供者范围。
  • 未观察到新的或非预期的安全性信号。

临床怎么用

  • 作者认为,观察到的阳性获益-风险特征可能为将奥瑞利珠单抗作为新诊断早期复发型多发性硬化患者的一线治疗提供信心。

局限性

  • 该单臂研究缺乏平行对照组,无法进行比较结局指标的对照。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Early treatment of multiple sclerosis (MS) reduces disease activity and the risk of long-term disease progression. Effectiveness of ocrelizumab is established in relapsing MS (RMS); however, data in early RMS are lacking. We evaluated the 4-year effectiveness and safety of ocrelizumab as a first-line therapy in treatment-naive patients with recently diagnosed relapsing-remitting MS (RRMS). METHODS: ENSEMBLE was a prospective, 4-year, international, multicenter, single-arm, open-label, phase IIIb study. Patients were treatment naive, aged 18-55 years, had early-stage RRMS with a disease duration ≤3 years, Expanded Disability Status Scale (EDSS) score ≤3.5, and ≥1 clinically reported relapse(s) or ≥1 signs of brain inflammatory activity on MRI in the prior 12 months. Patients received IV ocrelizumab 600 mg every 24 weeks. Effectiveness endpoints over 192 weeks were proportion of patients with no evidence of disease activity (NEDA-3; defined as absence of relapses, 24-week confirmed disability progression [CDP], and MRI measures, with prespecified MRI rebaselining at week 8), 24-week/48-week CDP and 24-week confirmed disability improvement, annualized relapse rate (ARR), mean change in EDSS score from baseline, and safety. Cognitive status, patient-reported outcomes, and serum neurofilament light chain (NfL) were assessed. Descriptive analysis was performed on the intention-to-treat population. RESULTS: Baseline characteristics (N = 678) were consistent with early-stage RRMS (n = 539 patients, 64.6% female, age 40 years and younger; median age: 31.0 years; duration since: MS symptom onset 0.78 years, RRMS diagnosis 0.24 years; mean baseline EDSS score [SD] 1.71 [0.95]). At week 192, most of the patients had NEDA-3 (n = 394/593, 66.4%), 85.0% had no MRI activity, 90.9% had no relapses, and 81.8% had no 24-week CDP over the study duration. Adjusted ARR at week 192 was low (0.020, 95% CI 0.015-0.027). NfL levels were reduced to and remained within the healthy donor range, by week 48 and week 192, respectively. No new or unexpected safety signals were observed. DISCUSSION: Disease activity based on clinical and MRI measures was absent in most of the patients treated with ocrelizumab over 4 years in the ENSEMBLE study. Safety was consistent with the known profile of ocrelizumab. Although this single-arm study was limited by lack of a parallel group for comparison of outcome measures, the positive benefit-risk profile observed may provide confidence to adopt ocrelizumab as a first-line treatment in newly diagnosed patients with early RMS. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that adult patients with early-stage MS who were treatment naive maintained low disease activity (NEDA-3) over 4 years with ocrelizumab treatment; no new safety signals were detected. TRIAL REGISTRATION INFORMATION: ClinicalTrials.gov Identifier NCT03085810; first submitted March 16, 2017; first patient enrolled: March 27, 2017; available at clinicaltrials.gov/ct2/show/NCT03085810.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Hartung HP, Benedict RHB, Berger T, et al. Ocrelizumab in Early-Stage Relapsing-Remitting Multiple Sclerosis: The Phase IIIb ENSEMBLE 4-Year, Single-Arm, Open-Label Trial. Neurology. 2024. PMID: 39626127. doi:10.1212/WNL.0000000000210049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。